Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Bioengineering and Translational Medicine is Scopus-indexed (Q1, CiteScore 13.9), WoS SCIE, DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2380-6761Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (all) | 24 / 669 | 96th | Q1 |
| Pharmaceutical Science | 10 / 191 | 95th | Q1 |
| Biotechnology | 28 / 325 | 91st | Q1 |
| Biomedical Engineering | 31 / 342 | 91st | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2020–present, best quartile Q1, CiteScore 13.9.
Bioengineering and Translational Medicine is Q1 in Medicine (all) (rank 24 of 669), Q1 in Pharmaceutical Science (rank 10 of 191) and Q1 in Biotechnology (rank 28 of 325), by CiteScore 2025. It is ranked in 4 subject areas in all.
Bioengineering and Translational Medicine is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 13.9, which places it in quartile Q1 at the 96th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.446, quartile Q1, with an H-index of 48.
The publisher lists an article processing charge of about US$2,890 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Bioengineering and Translational Medicine is published by John Wiley and Sons Inc. Its ISSN is 2380-6761.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Bioengineering and Translational Medicine has an h-index of 73 and a 2-year mean of 5.16 citations per paper (OpenAlex). Its Scopus CiteScore is 13.9, quartile Q1. On 2-year citations it ranks #39 of 646 Scopus journals in Medicine (all).
Bioengineering and Translational Medicine published 134 papers in 2025; its busiest recent year was 2022 with 185. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from United States (38.8%), China (28.8%) and Italy (3.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.